Realtime | Geld | Brief | Zeit |
---|---|---|---|
7,460 | 8,220 | 23:00 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.03. | Selvita S.A.: Selvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025 | 300 | PR Newswire | KRAKOW, Poland, March 27, 2025 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of Europe's leading preclinical CROs, has announced its financial results for 2024... ► Artikel lesen | |
21.11.24 | Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future | 205 | PR Newswire | KRAKÓW, Poland, Nov. 21, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published... ► Artikel lesen | |
SELVITA Aktie jetzt für 0€ handeln | |||||
24.09.24 | Selvita S.A.: Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024 | 447 | PR Newswire | KRAKÓW, Poland, Sept. 24, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q2 2024... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 43,800 | -0,86 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,300 | 0,00 % | Aktionäre von Palatin Technologies stimmen Reverse-Aktiensplit und Vorstandswahlen zu | ||
COSCIENS BIOPHARMA | 3,280 | -1,80 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
HALOZYME THERAPEUTICS | 53,38 | +1,48 % | Halozyme Therapeutics, Inc.: European Commission Approved DARZALEX Faspro for Adult Patients with Smouldering Multiple Myeloma | DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology
Approval represents critical advancement in early intervention for multiple myeloma
... ► Artikel lesen | |
ABCELLERA BIOLOGICS | 3,877 | -3,22 % | Leerink Partners startet Coverage für AbCellera mit "Outperform"-Rating | ||
GLOW LIFETECH | 0,026 | -7,14 % | Glow Lifetech Corp.: Glow Commissions New Automated Bottling Line Supporting Scale-Up and Launches CBG-Based Product in Ontario | Toronto, Ontario--(Newsfile Corp. - July 15, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting continued... ► Artikel lesen | |
BIO-RAD LABORATORIES | 217,50 | -0,68 % | BIO-RAD LABORATORIES, INC. - 10-Q, Quarterly Report | ||
AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
WHITEHAWK THERAPEUTICS | 1,590 | +1,92 % | Whitehawk Therapeutics, Inc.: Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals, Inc.: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) | Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10-million-patient marketAcquisition advances Paratek's vision... ► Artikel lesen | |
MINERVA NEUROSCIENCES | 1,700 | +1,80 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates | BURLINGTON, Mass., May 13, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates... ► Artikel lesen | |
APPLIED THERAPEUTICS | 0,382 | +0,87 % | Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting | Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute... ► Artikel lesen | |
GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs: Umsatzsprung im zweiten Quartal, Aktie dennoch unter Druck |